Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative

Pharmazie. 2020 Mar 20;75(2):94-101. doi: 10.1691/ph.2020.9815.

Abstract

An octahedral Pt (IV) prodrug, Cis-wog, containing a wogonin derivative as a bioactive axial ligand was designed and prepared to suppress DDR (DNA damage repair)-related proteins. In vitro biological studies indicated that a Pt (IV) prodrug with axially functional groups (Cis-wog) showed cytotoxicity superior to cisplatin and reversed its resistance against two pairs of cisplatin sensitive and resistant cell lines. Further mechanistic research revealed that the powerful antitumor activity of Cis-wog resulted from its suppression of JWA and its multi-interaction with XRCC1 to repair DNA single strand breaks (SSBs) caused by the introduction of wogonin. It is concluded that Cis-wog is a promising cytotoxic agent, which could be used for enhancing the antitumor activity of its corresponding Pt(II)-based drugs and reversing cisplatin resistance via decaying JWA-mediated SSBs repair pathways and inducing apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Antineoplastic Agents / pharmacology*
  • Apoptosis
  • Cell Line, Tumor
  • Cisplatin / pharmacology*
  • DNA Repair / drug effects*
  • Drug Resistance, Neoplasm / drug effects*
  • Flavanones / pharmacology*
  • Humans
  • Organoplatinum Compounds / pharmacology
  • Prodrugs / pharmacology
  • X-ray Repair Cross Complementing Protein 1 / metabolism

Substances

  • Antineoplastic Agents
  • Flavanones
  • Organoplatinum Compounds
  • Prodrugs
  • X-ray Repair Cross Complementing Protein 1
  • XRCC1 protein, human
  • wogonin
  • Cisplatin